Table 3.

Multivariate analysis for OS, EFS and RFS.

Covariates	OS			EFS			RFS §
Whole Cohort ‡ N = 125 ¶	HR	95%C.I.	p-value	HR	95%C.I.	p-value	HR	95%C.I.	p-value
Age ≥ 60 years	1.29	0.68–2.36	0.416	/	/	/	/	/	/
SPINK2high	2.45	1.48–4.07	<0.001	2.08	1.31–3.32	0.002	1.89	1.12–3.15	0.015
CR1	0.40	0.24–0.67	<0.001	0.33	0.21–0.52	<0.001	/	/	/
SCT ¥ in CR	0.11	0.02–0.37	0.0023	0.15	0.04–0.36	<0.001	0.11	0.02–0.37	0.003
DNMT3A	1.20	0.72–1.96	0.479	1.18	0.73–1.87	0.490	1.602	0.91–2.73	0.090
ELN2022 adv	1.78	1.02–3.02	0.037	1.86	0.94–3.43	0.060	2.16	1.21–3.73	0.007
IDH2	2.33	1.18–4.31	0.010	1.58	0.93–2.59	0.080	/	/	/
NPM1mut † N = 42 ¶	HR	95%C.I.	p-value	HR	95%C.I.	p-value	HR	95%C.I.	p-value
Age ≥ 60 years	9.10	2.36–34.39	0.001	7.53	2.01–27.45	0.002	3.58	0.92–12.13	0.046
SPINK2high	5.55	1.89–21.32	0.005	5.11	1.91–16.65	0.003	3.52	1.23–11.72	0.027
FLT3-ITD	2.54	0.94–8.18	0.085	3.9	1.37–11.94	0.017	2.47	0.88–7.84	0.100
DNMT3A	0.81	0.34–1.99	0.635	1.10	0.49–2.57	0.824	3.12	1.20–9.65	0.029

CR1: Complete remission at first induction; SCT in CR: stem cell transplantation administered after achieving complete remission; ELN2022 adv: ELN2022 adverse risk; ITD: internal tandem duplication; HR: hazard ratio; C.I.: confidence interval. ^§ For RFS analysis, only patients eventually achieving CR were included in the analysis in all cohorts (whole, N = 108; NPM1^mut, N = 38). ^‡ The covariates included in the multivariate analyses are those which demonstrated significant associations (p < 0.05) in univariate survival analyses (Table S5A,B). ^¥ These only include patients from the PWH SCT cohort (N = 37). ^† The covariates included in NPM1 analysis are those which are part of ELN2022’s criteria (FLT3-ITD) and generally associated with poor prognosis in NPM1^mut patients (age, DNMT3A). ^¶ Patients were only included if they had complete cytogenetic and mutational data which allowed them to be assigned to an ELN 2022 risk category.